418 related articles for article (PubMed ID: 23535565)
1. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
[TBL] [Abstract][Full Text] [Related]
2. Evaluating antithrombotic activity of HY023016 on rat hypercoagulable model.
Chen QF; Li YZ; Wang XH; Su YR; Cui S; Miao MX; Jiang ZZ; Jiang ML; Jiang AD; Chen X; Xu YG; Gong GQ
Eur J Pharmacol; 2016 Jun; 781():190-7. PubMed ID: 27085896
[TBL] [Abstract][Full Text] [Related]
3. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
4. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Aug; 98(2):333-8. PubMed ID: 17721615
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
6. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Pehrsson S; Johansson K; Kjaer M; Elg M
Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
J Thromb Haemost; 2007 Jun; 5(6):1237-42. PubMed ID: 17362226
[TBL] [Abstract][Full Text] [Related]
9. Dual-target synergistic antithrombotic mechanism of a dabigatran etexilate analogue (HY023016).
Wan S; Cui S; Jiang M; Wu Q; Ji Y; Xu Y; Gong G
Clin Exp Pharmacol Physiol; 2022 May; 49(5):567-576. PubMed ID: 35147244
[TBL] [Abstract][Full Text] [Related]
10. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
11. S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.
Rupin A; Marx I; Vallez MO; Mennecier P; Gloanec P; De Nanteuil G; Verbeuren TJ
J Thromb Haemost; 2011 Jul; 9(7):1375-82. PubMed ID: 21481181
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.
Chen D; Wang S; Diao X; Zhu Q; Shen H; Han X; Wang Y; Gong G; Xu Y
Bioorg Med Chem; 2015 Dec; 23(23):7405-16. PubMed ID: 26537784
[TBL] [Abstract][Full Text] [Related]
13. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
van Ryn J; Grottke O; Spronk H
Clin Lab Med; 2014 Sep; 34(3):479-501. PubMed ID: 25168938
[TBL] [Abstract][Full Text] [Related]
14. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice.
Lee IO; Kratz MT; Schirmer SH; Baumhäkel M; Böhm M
J Pharmacol Exp Ther; 2012 Nov; 343(2):253-7. PubMed ID: 22837011
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate.
Yang XZ; Diao XJ; Yang WH; Li F; He GW; Gong GQ; Xu YG
Bioorg Med Chem Lett; 2013 Apr; 23(7):2089-92. PubMed ID: 23466230
[TBL] [Abstract][Full Text] [Related]
16. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Clemens A; van Ryn J; Sennewald R; Yamamura N; Stangier J; Feuring M; Härtter S
Eur J Clin Pharmacol; 2012 May; 68(5):607-16. PubMed ID: 22252796
[TBL] [Abstract][Full Text] [Related]
17. Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits.
Yau JW; Liao P; Fredenburgh JC; Roberts RS; Weitz JI
Thromb Haemost; 2014 Jul; 112(1):79-86. PubMed ID: 24573541
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
Stangier J; Stähle H; Rathgen K; Roth W; Reseski K; Körnicke T
J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715
[TBL] [Abstract][Full Text] [Related]
19. Selective tissue factor/factor VIIa Inhibitor, ER-410660, and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects with a low risk of bleeding.
Nagakura T; Tabata K; Kira K; Hirota S; Clark R; Matsuura F; Hiyoshi H
Thromb Res; 2013 Aug; 132(2):271-9. PubMed ID: 23827699
[TBL] [Abstract][Full Text] [Related]
20. The pharmacology and therapeutic use of dabigatran etexilate.
Sarah S
J Clin Pharmacol; 2013 Jan; 53(1):1-13. PubMed ID: 23400738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
